Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.40 |
| ▸ | LIPG | Q9Y5X9 | 5/20 | 0.39 |
| ▸ | LPL | P06858 | 4/20 | 0.39 |
| ▸ | LIPE | Q05469 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.36 |
| ▸ | BCL9 | O00512 | 1/20 | 0.36 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | FBP1 | P09467 | 1/20 | 0.34 |
| ▸ | P4HB | P07237 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28810468 | 0.87 | PPARA (0.45) | HIF1ALIPGLPLPPARGPPARA | |
| SCHEMBL23582562 | 0.86 | PPARA (0.52) | DGAT1HIF1ALIPGLPLPPARG | |
| SCHEMBL4045906 | 0.80 | ELANE (0.41) | DGAT1HIF1ALIPGLPLCA1 | |
| SCHEMBL29539809 | 0.79 | DGAT1 (0.46) | DGAT1HIF1ALIPGLPLAAK1 | |
| SCHEMBL1407567 | 0.79 | DGAT1 (0.46) | DGAT1HIF1ALIPGLPLAAK1 | |
| SCHEMBL28469721 | 0.77 | AAK1 (0.40) | DGAT1HIF1ALIPGLPLAAK1 | |
| SCHEMBL21939759 | 0.77 | DGAT1 (0.45) | DGAT1HIF1ALIPGLPLAAK1 | |
| SCHEMBL29777947 | 0.76 | LPL (0.44) | LIPGLPLLIPECA1CA2 | |
| SCHEMBL5892571 | 0.76 | LPL (0.44) | LIPGLPLLIPECA1CA2 | |
| SCHEMBL19384284 | 0.76 | LIPG (0.43) | DGAT1HIF1ALIPGLPLAAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050234066-A1 | Alpha substituted carboxylic acids | AGOURON PHARMACEUTICALS, INC. | 2005-10-20 | — | — | US | disclosed |
| US-20050187266-A1 | Alpha substituted carboxylic acids | PFIZER INC | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234066-A1 | Alpha substituted carboxylic acids | PPARG, PPARA, PPARD | DGAT1 321/4885HIF1A 593/4885LIPG 740/4885 |
| US-20050187266-A1 | Alpha substituted carboxylic acids | PPARG, PPARA, PPARD | DGAT1 321/4885HIF1A 593/4885LIPG 740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.